Using RNA sequencing, Duke University investigators found that the channel protein aquaporin-3 is produced in great quantities once the Plasmodium parasite takes up residence in the liver prior to entering the bloodstream, according to findings published in the journal PLOS Pathogens. Inhibiting the AQP3 protein was linked with reductions in levels of the parasites.
The investigative Ebola treatment mAb114, which was developed from the antibodies of a patient who survived Ebola in 1995, will be dispatched for testing in the Democratic Republic of Congo, according to Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. Congo's health ministry requested access to the passive antibody treatment, and Fauci said the testing must be carried out in coordination with the World Health Organization.
Bio-Manguinhos, a unit of Brazil's Oswaldo Cruz Foundation, and Chembio Diagnostics entered into a commercialization agreement in Brazil for assays for dengue, Zika and chikungunya infections. The two have been collaborating since 2016 on viral tests.
A 212-patient, late-stage trial found that treatment with Imbruvica, or ibrutinib, plus Gazyva, or obinutuzumab, was associated with longer progression-free survival than chlorambucil plus Gazyva among patients with previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
Stem cell therapy developer Magenta Therapeutics is preparing for an initial public offering that could raise about $100 million to be used to advance its cell therapy candidate MGTA-456 toward a pivotal trial. The candidate is being developed as a therapy for inherited metabolic disorders, and the company is also developing a stem cell mobilization candidate.
Fifty-eight cases of Ebola have been reported in the Democratic Republic of Congo, including 27 deaths, according to the World Health Organization. WHO also said that over $25 million is coming from the US, Germany and the World Bank to support the response to the outbreak.
An update presented at a meeting of the World Federation of Hemophilia indicates that BioMarin Pharmaceutical's gene therapy candidate valoctocogene roxaparvovec continues to exhibit clinical benefits for patients with severe hemophilia A. Annualized bleeding rates were reduced by 97% while average factor VIII usage was reduced by 98%.
Some state Medicaid agencies are cutting payment rates for clinical laboratory testing below the Protecting Access to Medicare Act's fee schedule -- a move that is "drastic, unnecessary, and may threaten access to critical laboratory services," AACC and other organizations say. In a letter to CMS Secretary Seema Verma, organizations urged the agency to remind Medicaid directors about their obligation to "provide Medicaid reimbursement for laboratory services that is sufficient to ensure access to those services."
Australian regulators approved Genetic Signatures' antibiotic-resistant pathogens assay, the Extended Spectrum Beta-Lactamase and Carbapenemase Producing Organisms Detection Kit. The test can identify antibiotic-resistant pathogens within three hours and can rapidly detect carbapenem-resistant and 16 beta-lactam pathogen targets.
UniQure presented new data on its gene therapy candidate AMT-061 that showed the treatment was clinically beneficial for the 10 hemophilia B patients with pre-existing anti-AAV5 neutralizing antibodies who participated in the company's trial. The presentation was made at the annual meeting of the American Society of Gene and Cell Therapy in Chicago.
- Page 1